Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ascentage Selects PharmaBlock as Preferred Provider | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ascentage Selects PharmaBlock as Preferred Provider

PharmaBlock will support Ascentage in accelerating its drug development pipeline with R&D, manufacturing capacity, and technological solutions.

By: Contract Pharma

Contract Pharma Staff

PharmaBlock Sciences, Inc., a chemistry product and service provider for pharmaceutical R&D processes, has signed a strategic partnership agreement with Ascentage Pharma, a clinical-stage biotechnology company developing therapies for cancer, chronic hepatitis B (CHB), and age-related diseases to advance drug development and manufacturing.

PharmaBlock has served as long-term CDMO partner to Ascentage to advance development projects from discovery to preclinical and clinical manufacturing.

PharmaBlock will now serve as a preferred provider, and the two companies will continue to expand CDMO cooperation for current and future projects. PharmaBlock will support Ascentage in accelerating its drug development pipeline with R&D input and manufacturing capacity, along with its technological solutions.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to block apoptosis or programmed cell death. The company’s pipeline includes eight clinical drug candidates, including highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.

Ascentage is conducting more than 40 Phase I/II clinical trials in the U.S., Australia, and China. HQP1351, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation and a Fast Track Designation by the U.S. FDA, and an NDA for the drug has been submitted in China. To date, Ascentage was granted a total of eight ODDs from the FDA for four of its drug candidates.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics